Peptides: Legal Status by Jurisdiction — Full Reference
BPC-157 is FDA Category 2 (cannot be compounded) in the USA. Most GH peptides are Schedule 4 in Australia and unscheduled in the USA, UK, and EU.
| Measure | Value | Unit | Notes |
|---|---|---|---|
| Evidence Grade | N/A | grade | Regulatory reference data — not a therapeutic efficacy claim |
| Peptides in this table | 14 | peptides | BPC-157, TB-500, ipamorelin, CJC-1295, GHRP-2, GHRP-6, MK-677, AOD-9604, tesamorelin, semaglutide, selank, semax, epitalon, GHK-Cu |
| Jurisdictions covered | 5 | jurisdictions | USA, UK, Australia, Canada, EU (general) |
| WADA-prohibited peptides in table | 6+ | peptides | All GH secretagogues prohibited under S2; full list at wada-ama.org |
| USA CSA-scheduled peptides in table | 0 | count | None of the research peptides in this table are scheduled under the Controlled Substances Act |
| Australia Schedule 4 peptides in table | 11 | count | Most peptides in this table require a prescription in Australia under TGA Schedule 4 |
This is the most comprehensive publicly available summary of peptide legal status by jurisdiction. Laws change — verify current status before making legal decisions. This page reflects regulations as of April 2026.
How to Read This Table
- USA: Research chemical = not scheduled under CSA; legal to possess but not FDA-approved for human use; selling for human use violates FDA regulations
- UK: Not scheduled = not a controlled drug under the Misuse of Drugs Act (MDA 1971); may still require a prescription as an “unlicensed medicine” if used therapeutically
- Australia: Schedule 4 = Prescription Only under TGA Poisons Standard; unprescribed possession or import can trigger legal consequences
- Canada: No DIN = no Drug Identification Number; not approved; sold in gray market; Health Canada has authority to seize
- EU: No harmonized status = each EU member state regulates independently; Germany, France, and Poland have stricter approaches; most peptides are effectively unscheduled in most EU countries
Legal Status by Jurisdiction
| Peptide | USA | UK | Australia | Canada | EU (general) |
|---|---|---|---|---|---|
| BPC-157 | Research chemical (FDA Category 2 since 2023; cannot compound) | Not scheduled (GSL/unlicensed medicine) | Schedule 4 without Rx | No DIN; gray market | No harmonized status; generally unscheduled |
| TB-500 (Thymosin β-4) | Research chemical (unscheduled) | Not scheduled | Schedule 4 without Rx | No DIN; gray market | No harmonized status; generally unscheduled |
| Ipamorelin | Research chemical (unscheduled) | Not scheduled | Schedule 4 without Rx | No DIN; gray market | No harmonized status; unscheduled |
| CJC-1295 | Research chemical (unscheduled) | Not scheduled | Schedule 4 without Rx | No DIN; gray market | No harmonized status; unscheduled |
| GHRP-2 | Research chemical (unscheduled) | Not controlled | Schedule 4 without Rx | No DIN; gray market | No harmonized status; unscheduled |
| GHRP-6 | Research chemical (unscheduled) | Not controlled | Schedule 4 without Rx | No DIN; gray market | No harmonized status; unscheduled |
| MK-677 | Research chemical; not a peptide (small molecule) | Not scheduled | Schedule 4 without Rx | No DIN; gray market | No harmonized status; unscheduled |
| AOD-9604 | Research chemical (failed Phase 3 IND) | Not scheduled | Schedule 4 without Rx | No DIN; gray market | No harmonized status; unscheduled |
| Tesamorelin | Rx only (FDA-approved Egrifta; HIV lipodystrophy) | No licensed product (unlicensed import possible) | Schedule 4 Rx | Schedule F; Rx required | Not EMA-approved |
| Semaglutide | Rx only (Ozempic/Wegovy/Rybelsus) | Prescription only (Ozempic/Wegovy licensed) | Schedule 4 Rx (Ozempic licensed) | Prescription required (licensed) | Prescription only (EMA-approved) |
| Selank | Research chemical (unscheduled) | Not scheduled | Not specifically scheduled | No DIN; gray market | Varies (Russia-licensed; EU unscheduled) |
| Semax | Research chemical (unscheduled) | Not scheduled | Not specifically scheduled | No DIN; gray market | Varies (Russia-licensed; EU unscheduled) |
| Epitalon | Research chemical (unscheduled) | Not scheduled | Not specifically scheduled | No DIN; gray market | No harmonized status; unscheduled |
| GHK-Cu | Cosmetic/topical = legal; injectable = research chemical | Cosmetic legal; injectable unscheduled | Schedule 4 (injectable) | Cosmetic use legal; injectable gray market | Cosmetic use legal (EU Cosmetics Reg.); injectable unscheduled |
Sports Anti-Doping Status (WADA 2024)
The World Anti-Doping Code S2 list prohibits all GH-releasing peptides, their analogs, and any substance with similar biological effect. This is separate from domestic legality — a peptide can be legal to possess in the USA and still trigger a multi-year doping ban.
WADA-prohibited from the table above: ipamorelin, CJC-1295, GHRP-2, GHRP-6, sermorelin, TB-500 (thymosin beta-4 is explicitly listed), AOD-9604, tesamorelin, and any GH secretagogue. MK-677 is also prohibited as a growth hormone secretagogue despite not being a peptide. Selank, semax, epitalon, GHK-Cu, and collagen peptides are not currently on the WADA prohibited list.
Important Disclaimers
Laws change. The FDA’s Category 2 placement of BPC-157 in 2023 is an example of regulatory status shifting with no advance notice. Australia and Canada have pursued enforcement actions against peptide importers. This table is informational only — it does not constitute legal advice. Verify current status with a qualified attorney and the relevant regulatory authority before making decisions that could have legal consequences.
Related Pages
Sources
- FDA. Bulk Drug Substances Nominated for Compounding Under Section 503B — Category 2 list. 2023.
- WADA Prohibited List 2024. worldantidopingagency.org
- TGA (Therapeutic Goods Administration) Australia. Poisons Standard — Schedule 4. 2024.
- Health Canada. Drug Product Database. 2024.
Frequently Asked Questions
Is BPC-157 illegal in the USA?
BPC-157 is not a controlled substance under the Controlled Substances Act — it is not scheduled. Possession is not a federal crime. However, the FDA placed it on the Category 2 bulk drug substance list in 2023, which means licensed compounding pharmacies can no longer include it in formulations. It can still be sold as a 'research chemical' under a 'not for human use' label, which is the legal gray area most vendors use. Importing for personal use remains legally ambiguous.
Why are peptides Schedule 4 in Australia but unscheduled in the USA?
Australia's TGA uses a precautionary scheduling approach: if a substance has pharmacological activity and is used therapeutically, it defaults to Schedule 4 (Prescription Only) until proven otherwise. The USA's FDA uses a post-market enforcement model: substances are regulated as drugs if they are marketed with therapeutic claims, but unscheduled research chemicals with 'not for human use' labels occupy a gray area. Neither country has conducted comprehensive scheduling reviews for most research peptides — the regulatory differences reflect different default frameworks, not different safety assessments.